The potential role of new therapies in deep-vein thrombosis prophylaxis.

abstract：:Chronic lymphocytic leukemia (CLL) is a clonal proliferation of mature-appearing, but maturationally immature B cells; T cells are rarely involved. Most data suggest that CLL cells are frozen at an early step in maturation; this can be overcome by several techniques such as in vitro incubation with tumor promotors. Al...

journal_title：Seminars in hematology

authors： Gale RP,Foon KA

更新日期：1987-10-01 00:00:00

abstract：:The antiviral and antigrowth activity of interferon (IFN) makes this agent a promising approach to cancer therapy. Three tumors that are unusually sensitive to IFN-a are chronic myelogenous leukemia (CML) in the benign phase, hairy-cell leukemia, and the T-cell lymphomas associated with mycosis fungoides. Studies usin...

journal_title：Seminars in hematology

authors： Gutterman JU

更新日期：1988-07-01 00:00:00

abstract：:Current therapeutic strategies for autoimmune diseases primarily rely on immunosuppression, but global immune suppression results in an increased risk for severe infection and malignancy. In contrast, immuomodulation is another therapeutic approach employing intrinsic or environmental regulators that exert modulatory ...

journal_title：Seminars in hematology

authors： Kuwana M

更新日期：2016-04-01 00:00:00

abstract：:Continuous daily treatment with all-trans-retinoic acid (ATRA) in patients with acute promyelocytic leukemia has been associated with a marked decline in the plasma drug concentration at the time of relapse. Recent pharmacologic studies have attempted to determine the reasons for the progressive reduction of plasma co...

journal_title：Seminars in hematology

authors： Adamson PC

更新日期：1994-10-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure ...

journal_title：Seminars in hematology

authors： MacMillan ML,Walters MC,Gluckman E

更新日期：2010-01-01 00:00:00

abstract：:The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of ...

journal_title：Seminars in hematology

authors： Waldschmidt JM,Anand P,Knoechel B,Lohr JG

更新日期：2018-01-01 00:00:00

abstract：:Hydroxyurea (HU) is the first widely used treatment to have an impact on the severity of disease in adult patients with sickle cell anemia, but limited data are available for younger patients or those with variant genotypes. We reviewed 324 months of experience with HU in 16 patients from 5.3 to 18.4 years of age trea...

journal_title：Seminars in hematology

authors： Rogers ZR

更新日期：1997-07-01 00:00:00

abstract：:Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

journal_title：Seminars in hematology

authors： Yazdanbakhsh K,Zhong H,Bao W

更新日期：2013-01-01 00:00:00

abstract：:Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease af...

journal_title：Seminars in hematology

authors： Connors JM,Klimo P

更新日期：1987-04-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment for CML is allogeneic stem cell transplant. Unfortunately, a large proportion of CML patients are ineligible for such treatment and alternative...

journal_title：Seminars in hematology

authors： Barnes DJ,Melo JV

更新日期：2003-01-01 00:00:00

abstract：:Severe neutropenia renders patients susceptible to life-threatening bacterial and fungal infections. Despite improvements in supportive care and antimicrobial therapy, morbidity and mortality remains significant. Since the 1960s, granulocyte transfusions have been used to either treat or prevent serious infections in ...

journal_title：Seminars in hematology

authors： West KA,Conry-Cantilena C

更新日期：2019-10-01 00:00:00

abstract：:Serum vitamin B12 levels are often low in human immunodeficiency virus (HIV)-infected patients. However, only a few patients appear to have actual vitamin B12 deficiency. A low red cell folate level accompanying the low vitamin B12 level makes the presence of vitamin B12 deficiency more likely. Our experience suggests...

journal_title：Seminars in hematology

authors： Remacha AF,Cadafalch J

更新日期：1999-01-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML). With the exception of allogeneic stem cell transplantation, there is generally no curative treatment for these d...

journal_title：Seminars in hematology

authors： Fenaux P

更新日期：2004-04-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal proliferation of myeloid progenitors leading to erythrocytosis, thrombocytosis, or leukocytosis, and risk of hemorrhagic and thrombotic events, as well as ...

journal_title：Seminars in hematology

authors： Ferreira Cristina S,Polo B,Lacerda JF

更新日期：2018-10-01 00:00:00

abstract：:Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than...

journal_title：Seminars in hematology

authors： Hedner U

更新日期：2001-10-01 00:00:00

abstract：:CD59 and decay-accelerating factor (DAF) are glycosylphosphatidylinositol (GPI)-anchored complement regulatory proteins critical for regulating complement activation on the host cell surface. Defective expressions of CD59 or DAF caused by mutations in the genes coding for these proteins or genes involved in the biosyn...

journal_title：Seminars in hematology

authors： Kinoshita T

更新日期：2018-07-01 00:00:00

abstract：:Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

journal_title：Seminars in hematology

authors： Ho AD,Hensel M

更新日期：2006-04-01 00:00:00

abstract：:A retrospective study was conducted to determine treatment patterns for idiopathic thrombocytopenia purpura (ITP) across the US and to determine the cost of its treatment with high-dose intravenous immunoglobulin (IVIg) and anti-D therapy. Information on the incidence, treatment patterns, hospital care, and costs for ...

journal_title：Seminars in hematology

authors： Simpson KN,Coughlin CM,Eron J,Bussel JB

更新日期：1998-01-01 00:00:00

abstract：:The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

journal_title：Seminars in hematology

authors： Richardson P

更新日期：2005-10-01 00:00:00

abstract：:5-Aza-2'-deoxycytidine (decitabine; Dacogen, MGI Pharma, Inc, Bloomington, MN) is a cytidine analog that inhibits DNA methyltransferases resulting in loss of DNA methylation with subsequent gene re-expression. This compound was first synthesized over 40 years ago and since that time much information has been learned r...

journal_title：Seminars in hematology

authors： Kantarjian HM,Issa JP

更新日期：2005-07-01 00:00:00

abstract：:Patients with acute myeloid leukemia (AML) who achieve complete remission after induction therapy require post remission therapy (PRT) in order to remain disease free. The role of autologous hematopoietic cell transplantation (autoHCT) in the PRT setting is controversial and is largely based on older trials that were ...

journal_title：Seminars in hematology

authors： Yeshurun M,Wolach O

更新日期：2019-04-01 00:00:00

abstract：:Because optimal management of iron chelation therapy in patients with sickle cell disease and transfusional iron overload requires accurate determination of the magnitude of iron excess, a variety of techniques for evaluating iron overload are under development, including measurement of serum ferritin iron levels, x-r...

journal_title：Seminars in hematology

authors： Brittenham GM,Sheth S,Allen CJ,Farrell DE

更新日期：2001-01-01 00:00:00

abstract：:Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blasti...

journal_title：Seminars in hematology

authors： Campo E,Raffeld M,Jaffe ES

更新日期：1999-04-01 00:00:00

abstract：:The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：1999-10-01 00:00:00

abstract：:Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

journal_title：Seminars in hematology

authors： Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

更新日期：2010-07-01 00:00:00

abstract：:The molecular causes of hereditary spherocytosis (HS) have been unraveled in the past decade. No frequent defect is found, and nearly every family has a unique mutation. In dominant HS, nonsense and frameshift mutations of ankyrin, band 3, and beta-spectrin predominate. Recessive HS is most often due to compound heter...

journal_title：Seminars in hematology

authors： Eber S,Lux SE

更新日期：2004-04-01 00:00:00

abstract：:While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL. Moreover, the burden of therapy is high in a significant number of newly di...

journal_title：Seminars in hematology

authors： Jeha S

更新日期：2009-01-01 00:00:00

abstract：:Traditionally, acute myeloid leukemia (AML) has been diagnosed and classified based on the morphologic and cytochemical criteria of the French-American-British (FAB) classification system. However, more recent studies have demonstrated that the cytogenetic and molecular genetic abnormalities consistently associated wi...

journal_title：Seminars in hematology

authors： Willman CL

更新日期：1999-10-01 00:00:00

abstract：:The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

journal_title：Seminars in hematology

authors： Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

更新日期：1988-04-01 00:00:00

abstract：:Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder in which the patient's immune system reacts with a platelet autoantigen(s) resulting in thrombocytopenia due to immune-mediated platelet destruction and/or suppression of platelet production. Platelet membrane proteins, for reasons that are unclea...

journal_title：Seminars in hematology

authors： McMillan R

更新日期：2007-10-01 00:00:00